Last edition
News about "Phase 3 Clarity AD study"
Eisai, Biogen Secure China Approval for Once-Weekly Leqembi Subcutaneous Autoinjector
China approves Leqembi’s once-weekly subcutaneous autoinjector, offering patients with early Alzheimer’s disease a more convenient at-home treatment option.
Phase 3 Clarity AD Study | 04/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members